Fibrocell to Present at RBC Capital Markets 2016 Global Healthcare Conference
February 16 2016 - 8:05AM
Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene
therapy company translating personalized biologics into medical
breakthroughs, today announced that David Pernock, Chairman and
Chief Executive Officer, will present at the RBC Capital Markets
2016 Global Healthcare Conference at 2:35 p.m. ET on Tuesday,
February 23 in New York City.
A live audio webcast of Fibrocell’s presentation
will be available under the News & Events section of the
company’s website at http://ir.fibrocell.com/ and archived for 30
days. Please visit Fibrocell’s website several minutes prior
to the start of the broadcast to ensure adequate time for any
software download that may be necessary.
Fibrocell Trademarks Fibrocell™
and Fibrocell Science® are trademarks of Fibrocell Science, Inc.
and/or its affiliates. All other names may be trademarks of
their respective owners.
About Fibrocell Fibrocell is an
autologous cell and gene therapy company translating personalized
biologics into medical breakthroughs. Fibrocell’s most advanced
product candidate, azficel-T, uses its proprietary autologous
fibroblast technology and is in a Phase II clinical trial for the
treatment of vocal fold scarring resulting in chronic or severe
dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a
leader in synthetic biology, Fibrocell is also developing gene
therapies for skin and joint diseases using genetically-modified
autologous fibroblasts. Fibrocell is in preclinical
development of FCX-007, its orphan gene-therapy product candidate
for the treatment of recessive dystrophic epidermolysis bullosa
(RDEB). Fibrocell is also in preclinical development of
FCX-013, its gene-therapy product candidate for the treatment of
linear scleroderma. In addition, Fibrocell and Intrexon will
be commencing preclinical development of a gene therapy for the
treatment of chronic inflammatory and degenerative diseases of the
joint, including arthritis and related conditions. For more
information, visit www.fibrocell.com.
Investor Relations Contact:
John Woolford
Westwicke Partners
443.213.0506
john.woolford@westwicke.com
Media Relations Contact:
Michael Parks
484.356.7105
michael@pitch360inc.com
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jul 2023 to Jul 2024